Brian Wells to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Brian Wells has written about Diabetes Mellitus, Type 2.
Connection Strength
0.932
-
Wells BJ, Jain A, Arrigain S, Yu C, Rosenkrans WA, Kattan MW. Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care. 2008 Dec; 31(12):2301-6.
Score: 0.173
-
Wells BJ, Lenoir KM, Wagenknecht LE, Mayer-Davis EJ, Lawrence JM, Dabelea D, Pihoker C, Saydah S, Casanova R, Turley C, Liese AD, Standiford D, Kahn MG, Hamman R, Divers J. Detection of Diabetes Status and Type in Youth Using Electronic Health Records: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2020 10; 43(10):2418-2425.
Score: 0.098
-
Sabaté J, Burkholder-Cooley NM, Segovia-Siapco G, Oda K, Wells B, Orlich MJ, Fraser GE. Unscrambling the relations of egg and meat consumption with type 2 diabetes risk. Am J Clin Nutr. 2018 11 01; 108(5):1121-1128.
Score: 0.087
-
Pantalone KM, Misra-Hebert AD, Hobbs TM, Wells BJ, Kong SX, Chagin K, Dey T, Milinovich A, Weng W, Bauman JM, Burguera B, Zimmerman RS, Kattan MW. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. J Diabetes. 2018 Mar; 10(3):192-199.
Score: 0.082
-
Zimmerman RS, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, Chagin KM, Yu C, Sakurada B, Milinovich A, Weng W, Bauman JM, Pantalone KM. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. Diabetes Obes Metab. 2017 11; 19(11):1555-1561.
Score: 0.079
-
Pantalone KM, Wells BJ, Chagin KM, Ejzykowicz F, Yu C, Milinovich A, Bauman JM, Kattan MW, Rajpathak S, Zimmerman RS. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Diabetes Care. 2016 Sep; 39(9):1527-34.
Score: 0.075
-
Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. J Diabetes. 2016 Mar; 8(2):279-85.
Score: 0.069
-
Sun GE, Wells BJ, Yip K, Zimmerman R, Raghavan D, Kattan MW, Kashyap SR. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes Obes Metab. 2014 Mar; 16(3):276-83.
Score: 0.062
-
Al-Sayed NA, Gao T, Wells BJ, Yu C, Zimmerman RS. Angiotensin-converting enzyme inhibitors reduce albuminuria more than angiotensin receptor blockers in patients with type 2 diabetes. Endocr Pract. 2013 Jul-Aug; 19(4):579-86.
Score: 0.060
-
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012 Sep; 14(9):803-9.
Score: 0.055
-
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010 Jun; 33(6):1224-9.
Score: 0.048
-
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009 Jun; 46(2):145-54.
Score: 0.044